Experimental Dual GLP-1 Drug Reduces Heavy Drinking Days in Alcohol Use Disorder Trial

Source Summary

Pemvidutide, an investigational glucagon/GLP-1 dual receptor agonist, significantly reduced heavy drinking days per week in patients with moderate-to-severe alcohol use disorder in the phase II RECLAIM trial. The finding suggests a potential new therapeutic approach for treating AUD using a drug class primarily known for diabetes and weight management.

Why it matters

This trial result expands the potential clinical applications of GLP-1 receptor agonists beyond metabolic disease to a major public-health condition affecting millions globally.